Market Closed - Nasdaq 04:00:00 2024-02-21 pm EST 5-day change 1st Jan Change
15.62 USD -1.26% Intraday chart for NovoCure Limited 0.00% +4.62%
This article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Chart NovoCure Limited
More charts
NovoCure Limited is a global oncology company, which is principally engaged in the development, manufacturing and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua, for the treatment of solid tumor cancers. TTFields are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. TTFields therapy has applicability across solid tumor types and lines of therapy. It is conducting phase three pivotal studies evaluating the use of TTFields in non-small cell lung cancer (NSCLC), ovarian cancer, brain metastases from NSCLC, and pancreatic cancer. The Company's key priorities are to drive commercial adoption of Optune and Optune Lua, its commercial TTFields devices. The Company markets Optune in the United States, Germany, Japan and other countries. The Company markets Optune Lua in the United States and European Union. It also has a licence to market Optune in China, Hong Kong, Macau and Taiwan.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
15.62 USD
Average target price
26.14 USD
Spread / Average Target
+67.37%
Consensus
1st Jan change Capi.
+4.62% 1 691 M $
+2.69% 10 367 M $
+35.72% 9 563 M $
+12.70% 6 948 M $
-7.00% 5 497 M $
-0.02% 5 199 M $
+3.76% 5 007 M $
+9.90% 3 978 M $
-11.98% 3 347 M $
+0.62% 2 082 M $
Medical Equipment
  1. Stock
  2. Equities
  3. Stock NovoCure Limited - Nasdaq
  4. News NovoCure Limited
  5. Wells Fargo Downgrades NovoCure to Equalweight From Overweight, Adjusts Price Target to $107 From $89
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer